Comparison between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease

Author(s): Jie Zhang, Jiaqi Wang, Han Yu, Guanghua Wang, Junfang Zhang, Rui Zhu*, Xuebo Liu*, Jue Li*

Journal Name: Current Drug Metabolism

Volume 21 , Issue 10 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Statins are effective for patients with decreased low-density lipoprotein therapy.

Objective: The aim is to compare atorvastatin versus rosuvastatin on secondary percutaneous coronary intervention (PCI) rate and explore risk factors in coronary heart disease (CHD) patients.

Methods: A cohort study with 283 CHD subjects was launched from 2011 to 2015. Cox proportional hazards regression model, Receiver Operating Characteristic (ROC) and nomogram were used to compare the effect of atorvastatin and rosuvastatin on secondary PCI rate and disease risk factors. Even why the two statins had different effects based on gene expression profile analysis has been explored.

Results: Gene FFA (Freely fatty acid), AST (Aspartate Transaminase) and ALT (Alanine transaminase) showed the statistical difference between the four statin groups (P<0.05). In the AA group (Continuous Atorvastatin usage), albumin was a risk factor (Hazard Ratio (HR):1.076, 95%CI (1.001, 1.162), p<0.05). In the AR group (Start with Atorvastatin usage, then change to Rosuvastatin usage), ApoA was a protective factor (HR:0.004, 95%CI (0.001, 0.665), p<0.05). GLB (Galactosidase Beta) was a risk factor (HR:1.262, 95%CI (1.010, 1.576), p<0.05). In RR group (Continuous Rosuvastatin usage), ApoE was a protective factor (HR:0.943, 95%CI (0.890, 1.000), p<0.05). ALT was a risk factor (HR:1.030, 95%CI (1.000, 1.060), p<0.05).

Conclusion: Patients in the RA group had the lowest secondary PCI rate. ALT was a risk factor in the RR group. Gene Gpt (Glutamic Pyruvic Transaminase) encoded for one subtype of ALT had a significantly different expression in different statin groups.

Keywords: Percutaneous coronary intervention, coronary heart disease, rosuvastatin, atorvastatin, Gpt, ALT.

[1]
Townsend, N.; Wilson, L.; Bhatnagar, P.; Wickramasinghe, K.; Rayner, M.; Nichols, M. Cardiovascular disease in Europe: epidemiological update 2016. Eur. Heart J., 2016, 37(42), 3232-3245.
[http://dx.doi.org/10.1093/eurheartj/ehw334 ] [PMID: 27523477]
[2]
MacKenzie, G.; Greig, M.; Hay, I.; Pemberton, J. Competing risk analysis of factors related to long-term incidence of CHD. J. Epidemiol. Community Health, 2017, 71(1), 33-36.
[http://dx.doi.org/10.1136/jech-2016-207347 ] [PMID: 27485052]
[3]
Ueda, H.; Kido, A.; Matsuhisa, S.; Asawa, K.; Yoshida, N.; Tsujimoto, M.; Sasaki, Y.; Kuga, Y.; Yamasaki, M.; Ueda, K.; Shinohara, S.; Nishida, Y. Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial. Am. Heart J., 2016, 173, 134-142.
[http://dx.doi.org/10.1016/j.ahj.2015.12.014 ] [PMID: 26920606]
[4]
Hu, X.; Zhu, X.; Gao, L. Intensive nursing care by an electronic followup system to promote secondary prevention after percutaneous coronary intervention: a randomized trial. J. Cardiopulm. Rehabil. Prev., 2014, 34(6), 396-405.
[http://dx.doi.org/10.1097/HCR.0000000000000056 ] [PMID: 24667664]
[5]
García-Méndez, R.C.; Almeida-Gutierrez, E.; Serrano-Cuevas, L.; Sánchez-Díaz, J.S.; Rosas-Peralta, M.; Ortega-Ramirez, J.A.; Palomo-Villada, J.A.; Isordia-Salas, I.; Alonso-Bravo, R.M.; Borrayo-Sanchez, G. Reduction of no reflow with a loading dose of atorvastatin before primary angioplasty in patients with acute ST myocardial infarction. Arch. Med. Res., 2018, 49(8), 620-629.
[http://dx.doi.org/10.1016/j.arcmed.2018.10.006 ] [PMID: 30446246]
[6]
Veselka, J.; Hájek, P.; Tomašov, P.; Tesař, D.; Brůhová, H.; Matějovič, M.; Branny, M.; Studenčan, M.; Zemánek, D. Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study). Am. J. Cardiol., 2014, 113(3), 446-451.
[http://dx.doi.org/10.1016/j.amjcard.2013.10.026 ] [PMID: 24304551]
[7]
Sardella, G.; Conti, G.; Donahue, M.; Mancone, M.; Canali, E.; De Carlo, C.; Di Roma, A.; Calcagno, S.; Lucisano, L.; Fedele, F. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial. Catheter. Cardiovasc. Interv., 2013, 81(1), E36-E43.
[http://dx.doi.org/10.1002/ccd.24403 ] [PMID: 22517610]
[8]
Kumazaki, M.; Ando, H.; Ushijima, K.; Fujimura, A. Comparative effects of statins on murine cardiac gene expression profiles in normal mice. Eur. J. Pharmacol., 2013, 707(1-3), 71-77.
[http://dx.doi.org/10.1016/j.ejphar.2013.03.022 ] [PMID: 23524094]
[9]
Kunt, A.; Özcan, S.; Küçüker, A.; Odabaşi, D.; Sami Kunt, A. Efficacy of chronic statin therapy on major cardiac events after coronary artery bypass grafting: low-dose versus high-dose. Med Glas (Zenica), 2015, 12(2), 196-201.
[http://dx.doi.org/10.17392/795-15] [PMID: 26276659]
[10]
Eindhoven, J.A.; Onuma, Y.; Oemrawsingh, R.M.; Daemen, J.; van Nierop, J.W.; de Jaegere, P.P.; Boersma, E.; Serruys, P.W.; van Domburg, R.T. Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study. EuroIntervention, 2012, 7(12), 1420-1427.
[http://dx.doi.org/10.4244/EIJV7I12A222 ] [PMID: 22522553]
[11]
Sawano, M.; Kohsaka, S.; Abe, T.; Inohara, T.; Maekawa, Y.; Ueda, I.; Sueyoshi, K.; Suzuki, M.; Noma, S.; Numasawa, Y.; Miyata, H.; Fukuda, K.; Smolderen, K.G.; Spertus, J.A. Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry. PLoS One, 2017, 12(8)e0182687
[http://dx.doi.org/10.1371/journal.pone.0182687 ] [PMID: 28817616]
[12]
Deedwania, P.C.; Gupta, M.; Stein, M.; Ycas, J.; Gold, A.; Group, I.S. IRIS Study Group Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am. J. Cardiol., 2007, 99(11), 1538-1543.
[http://dx.doi.org/10.1016/j.amjcard.2007.01.028 ] [PMID: 17531577]
[13]
Schwartz, G.G.; Bolognese, M.A.; Tremblay, B.P.; Caplan, R.; Hutchinson, H.; Raza, A.; Cressman, M. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am. Heart J., 2004, 148(1)e4
[http://dx.doi.org/10.1016/j.ahj.2004.01.020 ] [PMID: 15215813]
[14]
Thondapu, V.; Kurihara, O.; Yonetsu, T.; Russo, M.; Kim, H.O.; Lee, H.; Soeda, T.; Minami, Y.; Jang, I.K. Comparison of rosuvastatin versus atorvastatin for coronary plaque stabilization. Am. J. Cardiol., 2019, 123(10), 1565-1571.
[http://dx.doi.org/10.1016/j.amjcard.2019.02.019 ] [PMID: 30851941]
[15]
Altunkeser, B.B.; Tuncez, A.; Ozturk, B.; Tezcan, H.; Ates, M.S.; Yilmaz, C.; Yalcin, M.U.; Aygul, N.; Demir, K. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome. Coron. Artery Dis., 2019, 30(4), 285-290.
[http://dx.doi.org/10.1097/MCA.0000000000000715 ] [PMID: 30741744]
[16]
Firouzi, A.; Kazem Moussavi, A.; Mohebbi, A.; Alemzadeh-Ansari, M.J.; Kiani, R.; Sanati, H.R.; Mohebbi, B.; Shakerian, F.; Zahedmehr, A.; Ansari-Ramandi, M.M.; Oni Heris, S.; Ghaleshi, B.; Ghorbani, F. Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention. J. Cardiovasc. Thorac. Res., 2018, 10(3), 149-152.
[http://dx.doi.org/10.15171/jcvtr.2018.24 ] [PMID: 30386535]
[17]
Kaya, A.; Kurt, M.; Tanboğa, I.H.; Işik, T.; Ekinci, M.; Aksakal, E.; Kaya, Y.; Topçu, S.; Sevimli, S. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial). Acta Cardiol., 2013, 68(5), 489-494.
[http://dx.doi.org/10.1080/AC.68.5.2994472 ] [PMID: 24283110]
[18]
Khurana, S.; Gupta, S.; Bhalla, H.; Nandwani, S.; Gupta, V. Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome. J. Pharmacol. Pharmacother., 2015, 6(3), 130-135.
[http://dx.doi.org/10.4103/0976-500X.162011 ] [PMID: 26311995]
[19]
Kurtoglu, E.; Balta, S.; Sincer, I.; Altas, Y.; Atas, H.; Yilmaz, M.; Korkmaz, H.; Erdem, K.; Akturk, E.; Demirkol, S.; Can, C. Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease. Angiology, 2014, 65(9), 788-793.
[http://dx.doi.org/10.1177/0003319713507333 ] [PMID: 24163120]
[20]
Pitt, B.; Loscalzo, J.; Monyak, J.; Miller, E.; Raichlen, J. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am. J. Cardiol., 2012, 109(9), 1239-1246.
[http://dx.doi.org/10.1016/j.amjcard.2011.12.015 ] [PMID: 22360820]
[21]
Ovrakh, T.; Serik, S.; Kochubiei, O. Impact of atorvastatin and rosuvastatin on residual on-clopidogrel treatment platelet reactivity in patients with ischemic heart disease and type 2 diabetes mellitus after acute coronary syndrome. Georgian Med. News, 2017, (265), 7-14.
[PMID: 28574378]
[22]
Qian, C.; Wei, B.; Ding, J.; Wu, H.; Cai, X.; Li, B.; Wang, Y. Meta-analysis comparing the effects of rosuvastatin versus atorvastatin on regression of coronary atherosclerotic plaques. Am. J. Cardiol., 2015, 116(10), 1521-1526.
[http://dx.doi.org/10.1016/j.amjcard.2015.08.010 ] [PMID: 26385518]
[23]
Breitling, L.P.; Rothenbacher, D.; Grandi, N.C.; März, W.; Brenner, H. Prognostic usefulness of free fatty acids in patients with stable coronary heart disease. Am. J. Cardiol., 2011, 108(4), 508-513.
[http://dx.doi.org/10.1016/j.amjcard.2011.03.076 ] [PMID: 21624537]
[24]
Kikuchi, T. Studies on myocardial free fatty acids (ffa) metabolism of human heart by coronary sinus catheterization. 1. myocardial ffa metabolism in health and disease, and effects of several hormones on it. Nippon Naika Gakkai Zasshi, 1964, 53, 1000-1010.
[http://dx.doi.org/10.2169/naika.53.1000 ] [PMID: 14291635]
[25]
Sharrock, N.E.; Nye, E.R. Patients with coronary heart disease: effect of recreational activities on heart rate, blood lactate and free fatty acids. N. Z. Med. J., 1971, 74(471), 78-83.
[PMID: 5291716]
[26]
He, L.Y.; Zhao, J.F.; Han, J.L.; Shen, S.S.; Chen, X.J. Correlation between serum free fatty acids levels and Gensini score in elderly patients with coronary heart disease. J. Geriatr. Cardiol., 2014, 11(1), 57-62.
[http://dx.doi.org/10.3969/j.issn.1671-5411.2014.01.003] [PMID: 24748883]
[27]
Pickart, L. Increased ratio of plasma free fatty acids to albumin during normal aging and in patients with coronary heart disease. Atherosclerosis, 1983, 46(1), 21-28.
[http://dx.doi.org/10.1016/0021-9150(83)90160-0 ] [PMID: 6838692]
[28]
Hu, M.; Cheung, B.M.; Tomlinson, B. Safety of statins: an update. Ther. Adv. Drug Saf., 2012, 3(3), 133-144.
[http://dx.doi.org/10.1177/2042098612439884 ] [PMID: 25083232]
[29]
Riche, D.M.; Fleming, J.W.; Malinowski, S.S.; Black, C.A.; Miller, K.H.; Wofford, M.R. Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. Ann. Pharmacother., 2014, 48(1), 137-141.
[http://dx.doi.org/10.1177/1060028013507239 ] [PMID: 24259612]
[30]
Adults, J.C.D.C.P.T.D.i. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi, 2007, 35(5), 390-419.
[PMID: 17711682]
[31]
Nelson, J.J.; Liao, D.; Sharrett, A.R.; Folsom, A.R.; Chambless, L.E.; Shahar, E.; Szklo, M.; Eckfeldt, J.; Heiss, G. Serum albumin level as a predictor of incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Am. J. Epidemiol., 2000, 151(5), 468-477.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a010232 ] [PMID: 10707915]
[32]
Chien, S.C.; Chen, C.Y.; Leu, H.B.; Su, C.H.; Yin, W.H.; Tseng, W.K.; Wu, Y.W.; Lin, T.H.; Chang, K.C.; Wang, J.H.; Wu, C.C.; Yeh, H.I.; Chen, J.W. Association of low serum albumin concentration and adverse cardiovascular events in stable coronary heart disease. Int. J. Cardiol., 2017, 241, 1-5.
[http://dx.doi.org/10.1016/j.ijcard.2017.04.003 ] [PMID: 28413113]
[33]
Wang, Q.; Huang, C.R.; Jiang, M.; Zhu, Y.Y.; Wang, J.; Chen, J.; Shi, J.H. Binding interaction of atorvastatin with bovine serum albumin: spectroscopic methods and molecular docking. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2016, 156, 155-163.
[http://dx.doi.org/10.1016/j.saa.2015.12.003 ] [PMID: 26688207]
[34]
Schaefer, J.R.; Schweer, H.; Ikewaki, K.; Stracke, H.; Seyberth, H.J.; Kaffarnik, H.; Maisch, B.; Steinmetz, A. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis, 1999, 144(1), 177-184.
[http://dx.doi.org/10.1016/S0021-9150(99)00053-2 ] [PMID: 10381291]
[35]
Li, X.P.; Gong, H.R.; Huang, X.S.; Huang, W.Y.; Zhao, S.P. The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome. Lipids Health Dis., 2013, 12, 133.
[http://dx.doi.org/10.1186/1476-511X-12-133 ] [PMID: 24016248]
[36]
Boekholdt, S.M.; Arsenault, B.J.; Hovingh, G.K.; Mora, S.; Pedersen, T.R.; Larosa, J.C.; Welch, K.M.; Amarenco, P.; Demicco, D.A.; Tonkin, A.M.; Sullivan, D.R.; Kirby, A.; Colhoun, H.M.; Hitman, G.A.; Betteridge, D.J.; Durrington, P.N.; Clearfield, M.B.; Downs, J.R.; Gotto, A.M., Jr; Ridker, P.M.; Kastelein, J.J. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation, 2013, 128(14), 1504-1512.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.002670 ] [PMID: 23965489]
[37]
Rashid, S.; Uffelman, K.D.; Barrett, P.H.; Lewis, G.F. Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit. Circulation, 2002, 106(23), 2955-2960.
[http://dx.doi.org/10.1161/01.CIR.0000038303.84249.4A ] [PMID: 12460878]
[38]
Takagi, H.; Umemoto, T.; Group, A. ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles. Am. J. Cardiol., 2014, 113(2), 292-301.
[http://dx.doi.org/10.1016/j.amjcard.2013.08.043 ] [PMID: 24230979]
[39]
Davies, D.F.; Clark, A. Increase of gamma g-globulin in coronary heart disease. J. Atheroscler. Res., 1968, 8(4), 724-730.
[http://dx.doi.org/10.1016/S0368-1319(68)80030-4 ] [PMID: 4176006]
[40]
Donnelly, L.A.; Palmer, C.N.; Whitley, A.L.; Lang, C.C.; Doney, A.S.; Morris, A.D.; Donnan, P.T. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet. Genomics, 2008, 18(4), 279-287.
[http://dx.doi.org/10.1097/FPC.0b013e3282f60aad ] [PMID: 18334912]
[41]
Yu, Y.; Jin, L.; Zhuang, Y.; Hu, Y.; Cang, J.; Guo, K. Cardioprotective effect of rosuvastatin against isoproterenol-induced myocardial infarction injury in rats. Int. J. Mol. Med., 2018, 41(6), 3509-3516.
[http://dx.doi.org/10.3892/ijmm.2018.3572 ] [PMID: 29568858]
[42]
Seif El-Din, S.H.; El-Lakkany, N.M.; El-Naggar, A.A.; Hammam, O.A.; Abd El-Latif, H.A.; Ain-Shoka, A.A.; Ebeid, F.A. Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats. Res. Pharm. Sci., 2015, 10(4), 275-287.
[PMID: 26600855]
[43]
Chang, Y.; Li, H.; Ren, H.; Xu, H.; Hu, P. Misclassification of chronic hepatitis B natural history phase: Insight from new ALT, AST, AKP, and GGT reference intervals in Chinese children. Clin. Chim. Acta, 2019, 489, 61-67.
[http://dx.doi.org/10.1016/j.cca.2018.11.034 ] [PMID: 30503274]
[44]
Isherwood, J.; Garcea, G.; Williams, R.; Metcalfe, M.; Dennison, A.R. Serology and ultrasound for diagnosis of choledocholithiasis. Ann. R. Coll. Surg. Engl., 2014, 96(3), 224-228.
[http://dx.doi.org/10.1308/003588414X13814021678033 ] [PMID: 24780789]
[45]
Giesen, P.L.; Peltenburg, H.G.; de Zwaan, C.; Janson, P.C.; Flendrig, J.G.; Hermens, W.T. Greater than expected alanine aminotransferase activities in plasma and in hearts of patients with acute myocardial infarction. Clin. Chem., 1989, 35(2), 279-283.
[http://dx.doi.org/10.1093/clinchem/35.2.279 ] [PMID: 2914373]
[46]
Peltz-Sinvani, N.; Klempfner, R.; Ramaty, E.; Sela, B.A.; Goldenberg, I.; Segal, G. Low ALT levels independently associated with 22-year all-cause mortality among coronary heart disease patients. J. Gen. Intern. Med., 2016, 31(2), 209-214.
[http://dx.doi.org/10.1007/s11606-015-3480-6 ] [PMID: 26245731]
[47]
Sabin, C.A.; Ryom, L.; Kovari, H.; Kirk, O.; de Wit, S.; Law, M.; Reiss, P.; Dabis, F.; Pradier, C.; El-Sadr, W.; Monforte, Ad.; Kamara, D.; Phillips, A.N.; Lundgren, J.D. Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study. J. Acquir. Immune Defic. Syndr., 2013, 63(4), 456-463.
[http://dx.doi.org/10.1097/QAI.0b013e318291cd29 ] [PMID: 23535291]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 10
Year: 2020
Page: [818 - 828]
Pages: 11
DOI: 10.2174/1389200221666200310110410
Price: $65

Article Metrics

PDF: 39
HTML: 1